FDx Advisors Inc. Increases Stake in ICON Public Limited (NASDAQ:ICLR)

FDx Advisors Inc. raised its holdings in shares of ICON Public Limited (NASDAQ:ICLR) by 13.6% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 3,527 shares of the medical research company’s stock after buying an additional 422 shares during the period. FDx Advisors Inc.’s holdings in ICON Public were worth $740,000 at the end of the most recent quarter.

A number of other hedge funds have also modified their holdings of the company. Kornitzer Capital Management Inc. KS boosted its position in shares of ICON Public by 40.6% in the fourth quarter. Kornitzer Capital Management Inc. KS now owns 97,102 shares of the medical research company’s stock worth $20,363,000 after purchasing an additional 28,050 shares during the period. Foyston Gordon & Payne Inc bought a new position in shares of ICON Public in the third quarter worth approximately $11,672,000. Icon Wealth Advisors LLC boosted its position in shares of ICON Public by 861.1% in the third quarter. Icon Wealth Advisors LLC now owns 13,215 shares of the medical research company’s stock worth $3,797,000 after purchasing an additional 11,840 shares during the period. Entropy Technologies LP boosted its position in shares of ICON Public by 472.2% in the fourth quarter. Entropy Technologies LP now owns 6,174 shares of the medical research company’s stock worth $1,295,000 after purchasing an additional 5,095 shares during the period. Finally, Tributary Capital Management LLC boosted its position in shares of ICON Public by 116.1% in the fourth quarter. Tributary Capital Management LLC now owns 3,950 shares of the medical research company’s stock worth $828,000 after purchasing an additional 2,122 shares during the period. 95.61% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on ICLR shares. Leerink Partners restated an “outperform” rating and set a $255.00 target price (down previously from $270.00) on shares of ICON Public in a research report on Tuesday, November 19th. William Blair restated an “outperform” rating on shares of ICON Public in a research report on Tuesday, January 14th. Citigroup dropped their target price on shares of ICON Public from $300.00 to $290.00 and set a “buy” rating for the company in a research report on Monday, January 6th. JPMorgan Chase & Co. dropped their target price on shares of ICON Public from $280.00 to $265.00 and set an “overweight” rating for the company in a research report on Monday, February 3rd. Finally, Baird R W lowered shares of ICON Public from a “strong-buy” rating to a “hold” rating in a research report on Thursday, October 24th. Four investment analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, ICON Public currently has a consensus rating of “Moderate Buy” and a consensus price target of $283.92.

ICON Public Trading Up 5.5 %

Shares of ICLR opened at $201.84 on Friday. ICON Public Limited has a twelve month low of $181.51 and a twelve month high of $347.72. The company has a market cap of $16.65 billion, a P/E ratio of 22.50, a P/E/G ratio of 1.73 and a beta of 1.19. The company has a current ratio of 1.34, a quick ratio of 1.34 and a debt-to-equity ratio of 0.35. The company’s fifty day simple moving average is $203.04 and its 200-day simple moving average is $246.13.

ICON Public (NASDAQ:ICLR) last announced its earnings results on Wednesday, February 19th. The medical research company reported $3.42 earnings per share for the quarter, beating the consensus estimate of $3.41 by $0.01. ICON Public had a net margin of 9.00% and a return on equity of 11.91%. The business had revenue of $2.04 billion for the quarter, compared to the consensus estimate of $2.04 billion. As a group, analysts expect that ICON Public Limited will post 13.44 EPS for the current year.

About ICON Public

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.